[Form 4] MIRA PHARMACEUTICALS, INC. Insider Trading Activity
MIRA Pharmaceuticals' CEO and director received repriced, fully vested stock options totaling 300,000 shares. The company’s board lowered the exercise price on two existing option grants—from $5.00 and $6.50—to $1.38, while leaving all other terms unchanged. Each repriced grant covers 150,000 options and remains exercisable into common stock with specified expiration dates in 2033. The disclosure shows the holdings are held directly by the reporting person and that the repricing was approved by the board, which materially changes the economic value of the previously issued awards.
Il CEO e il direttore di MIRA Pharmaceuticals hanno ricevuto opzioni azionarie repricete, completamente vestite, per un totale di 300.000 azioni. Il consiglio dell'azienda ha abbassato il prezzo di esercizio di due concessioni di opzioni esistenti — da 5,00 $ e 6,50 $ a 1,38 $, mantenendo invariate tutte le altre condizioni. Ogni concessione repriced copre 150.000 opzioni e resta esercitabile in azioni ordinarie con scadenze specificate nel 2033. La disclosure indica che le partecipazioni sono detenute direttamente dalla persona che presenta la segnalazione e che la repricing è stata approvata dal consiglio, cambiando sostanzialmente il valore economico dei premi emessi in precedenza.
El CEO y director de MIRA Pharmaceuticals recibió opciones de acciones repricadas, totalmente vestidas, por un total de 300.000 acciones. La junta de la empresa redujo el precio de ejercicio de dos adjudicaciones de opciones existentes, de 5,00 $ y 6,50 $, a 1,38 $, dejando intactos todos los demás términos. Cada adjudicación repriced cubre 150.000 opciones y continúa siendo ejercitable en acciones comunes con fechas de vencimiento especificadas en 2033. La divulgación muestra que las participaciones están directamente en posesión de la persona que presenta el informe y que la repricing fue aprobada por la junta, lo que cambia sustancialmente el valor económico de las recompensas emitidas previamente.
MIRA Pharmaceuticals의 CEO 겸 이사는 총 30만 주의 재가격화되고 완전히 귀속된 주식 옵션을 받았습니다. 회사의 이사회는 두 개의 기존 옵션 부여의 행사 가격을 5.00달러와 6.50달러에서 1.38달러로 낮추면서 다른 모든 조건은 변경하지 않았습니다. 각 재가격화된 부여는 150,000주의 옵션을 포함하며 2033년에 명시된 만기일로 일반 주식으로 행사할 수 있습니다. 공시에는 보유가 보고인에 의해 직접 보유되고 재가격화가 이사회에서 승인되었으며, 이는 이전에 발행된 보상에 대한 경제적 가치를 실질적으로 변화시킵니다.
Le PDG et administrateur de MIRA Pharmaceuticals ont reçu des options d'actions repricées, entièrement acquises, totalisant 300 000 actions. Le conseil d'administration de l'entreprise a abaissé le prix d’exercice sur deux attributions d’options existantes — de 5,00 $ et 6,50 $ — à 1,38 $, tout le reste restant inchangé. Chaque attribution repriced couvre 150 000 options et demeure exerçable en actions ordinaires avec des dates d’expiration spécifiées en 2033. La divulgation indique que les positions sont détenues directement par la personne déclarant et que la repricing a été approuvée par le conseil, ce qui modifie substantiellement la valeur économique des récompenses émises précédemment.
Der CEO und Direktor von MIRA Pharmaceuticals erhielt neu berechnete, vollständig vestete Aktienoptionen im Gesamtvolumen von 300.000 Aktien. Der Vorstand des Unternehmens senkte den Ausübungspreis zweier bestehender Optionszuweisungen von 5,00 $ bzw. 6,50 $ auf 1,38 $, während alle anderen Bedingungen unverändert blieben. Jede neu bewertete Zuweisung umfasst 150.000 Optionen und bleibt bis zu den im Jahr 2033 festgelegten Verfallsterminen ausübbar. Die Offenlegung zeigt, dass die Bestände direkt von der meldenden Person gehalten werden und dass die Neubewertung vom Vorstand genehmigt wurde, was den wirtschaftlichen Wert der zuvor ausgegebenen Zuwendungen wesentlich verändert.
تلقى الرئيس التنفيذي ومدير MIRA Pharmaceuticals خيارات أسهم معاد تسعيرها، مكتملة الاستحقاق، بإجمالي 300,000 سهم. خفض مجلس إدارة الشركة سعر التمرين على منحين خيارين قائمتين — من 5.00 دولارات و6.50 دولارات — إلى 1.38 دولار، مع بقاء جميع الشروط الأخرى دون تغيير. تغطي كل منح مُعاد تسعيره 150,000 خيار وتظل قابلة للتطبيق في الأسهم العادية مع تواريخ انتهاء محددة في 2033. توضّح الإفصاحات أن الحيازات مملوكة مباشرة من الشخص المبلغ عنه وأن إعادة التسعير قد تمت الموافقة عليها من قبل المجلس، مما يغيّر بشكل جوهري القيمة الاقتصادية للحوافز الممنوحة سابقاً.
MIRA制药的CEO兼董事获得了总计30万股、重新定价且已完全归属的股票期权。 公司董事会将两项现有期权授予的行权价从5.00美元和6.50美元降至1.38美元，同时保持其他条款不变。每项重新定价的授予覆盖150,000份期权，仍可在2033年的指定到期日以普通股行使。披露显示这些持股直接由报告人本人持有，且重新定价已获董事会批准，这在经济上实质性地改变了此前发行奖励的价值。
- 300,000 options granted/repriced to $1.38 increases management alignment with potential upside
- Options are fully vested, providing clear, immediate economic recognition to the reporting person
- Board approval documented for the repricing action
- Exercise prices reduced significantly from $5.00 and $6.50 to $1.38, which materially enhances insider value
- Potential shareholder dilution upon exercise of 300,000 options
- Governance concerns may arise because repricing vested awards increases insider compensation without disclosed shareholder approval
Insights
TL;DR: Board-approved repricing materially increases intrinsic value of executive options but does not change share count or expiration terms.
The board reduced exercise prices from $5.00 and $6.50 to $1.38 on two option grants totaling 300,000 options now fully vested and held directly by the CEO/director. This raises the immediate economic value of those awards and strengthens executive upside if the stock appreciates above the new strike. It does not, per the filing, alter expiration dates or other contractual terms beyond price. For investors, the action improves management compensation economics but introduces potential dilution upon exercise.
TL;DR: Repricing vested options to a much lower strike can create shareholder governance concerns despite retaining original terms.
Repricing vested awards from $5.00 and $6.50 down to $1.38 significantly increases award value to the reporting person without new grant approvals disclosed. While the filing states all other terms are unchanged, such repricing can attract scrutiny over alignment with shareholder interests and customary anti-dilution or clawback protections. The move is material to governance assessments and may prompt questions about board rationale and shareholder approval practices.
Il CEO e il direttore di MIRA Pharmaceuticals hanno ricevuto opzioni azionarie repricete, completamente vestite, per un totale di 300.000 azioni. Il consiglio dell'azienda ha abbassato il prezzo di esercizio di due concessioni di opzioni esistenti — da 5,00 $ e 6,50 $ a 1,38 $, mantenendo invariate tutte le altre condizioni. Ogni concessione repriced copre 150.000 opzioni e resta esercitabile in azioni ordinarie con scadenze specificate nel 2033. La disclosure indica che le partecipazioni sono detenute direttamente dalla persona che presenta la segnalazione e che la repricing è stata approvata dal consiglio, cambiando sostanzialmente il valore economico dei premi emessi in precedenza.
El CEO y director de MIRA Pharmaceuticals recibió opciones de acciones repricadas, totalmente vestidas, por un total de 300.000 acciones. La junta de la empresa redujo el precio de ejercicio de dos adjudicaciones de opciones existentes, de 5,00 $ y 6,50 $, a 1,38 $, dejando intactos todos los demás términos. Cada adjudicación repriced cubre 150.000 opciones y continúa siendo ejercitable en acciones comunes con fechas de vencimiento especificadas en 2033. La divulgación muestra que las participaciones están directamente en posesión de la persona que presenta el informe y que la repricing fue aprobada por la junta, lo que cambia sustancialmente el valor económico de las recompensas emitidas previamente.
MIRA Pharmaceuticals의 CEO 겸 이사는 총 30만 주의 재가격화되고 완전히 귀속된 주식 옵션을 받았습니다. 회사의 이사회는 두 개의 기존 옵션 부여의 행사 가격을 5.00달러와 6.50달러에서 1.38달러로 낮추면서 다른 모든 조건은 변경하지 않았습니다. 각 재가격화된 부여는 150,000주의 옵션을 포함하며 2033년에 명시된 만기일로 일반 주식으로 행사할 수 있습니다. 공시에는 보유가 보고인에 의해 직접 보유되고 재가격화가 이사회에서 승인되었으며, 이는 이전에 발행된 보상에 대한 경제적 가치를 실질적으로 변화시킵니다.
Le PDG et administrateur de MIRA Pharmaceuticals ont reçu des options d'actions repricées, entièrement acquises, totalisant 300 000 actions. Le conseil d'administration de l'entreprise a abaissé le prix d’exercice sur deux attributions d’options existantes — de 5,00 $ et 6,50 $ — à 1,38 $, tout le reste restant inchangé. Chaque attribution repriced couvre 150 000 options et demeure exerçable en actions ordinaires avec des dates d’expiration spécifiées en 2033. La divulgation indique que les positions sont détenues directement par la personne déclarant et que la repricing a été approuvée par le conseil, ce qui modifie substantiellement la valeur économique des récompenses émises précédemment.
Der CEO und Direktor von MIRA Pharmaceuticals erhielt neu berechnete, vollständig vestete Aktienoptionen im Gesamtvolumen von 300.000 Aktien. Der Vorstand des Unternehmens senkte den Ausübungspreis zweier bestehender Optionszuweisungen von 5,00 $ bzw. 6,50 $ auf 1,38 $, während alle anderen Bedingungen unverändert blieben. Jede neu bewertete Zuweisung umfasst 150.000 Optionen und bleibt bis zu den im Jahr 2033 festgelegten Verfallsterminen ausübbar. Die Offenlegung zeigt, dass die Bestände direkt von der meldenden Person gehalten werden und dass die Neubewertung vom Vorstand genehmigt wurde, was den wirtschaftlichen Wert der zuvor ausgegebenen Zuwendungen wesentlich verändert.
FAQ
What transactions were reported for MIRA (MIRA) by the CEO/director?
How many options are exercisable and what is the total potential common stock underlying them?
Were the terms other than price changed for the repriced options?
Who approved the option repricing for MIRA?
Do the repriced options introduce immediate dilution to existing shareholders?
